Androgen-regulated gastrin-releasing peptide receptor expression in androgen-dependent human prostate tumor xenografts by Schroeder, R.P.J. (Rogier) et al.
Androgen-Regulated Gastrin-Releasing Peptide Receptor Expression
in Androgen-Dependent Human Prostate Tumor Xenografts
Rogier P.J. Schroeder1,2*, M. de Visser1*, Wytske M. van Weerden2, Corrina M.A. de
Ridder2, Suzanne Reneman2, Marleen Melis1, Wout A.P. Breeman1, Eric P. Krenning1,
Marion de Jong1.
1Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands.
2Experimental Urology, Erasmus MC, Rotterdam, The Netherlands.
* Both authors contributed equally to this manuscript
Correspondence address:
Rogier P.J. Schroeder, MD, MSc
Erasmus MC Rotterdam; room Be331 (JNI)
Dr. Molenwaterplein 50
3015 GE Rotterdam
The Netherlands
Phone: +31107043381
Fax: +31107044661
E-mail: m.hendriks-dejong@erasmusmc.nl
1Abstract
Human prostate cancer (PC) overexpresses the gastrin-releasing peptide receptor
(GRPR). Radiolabelled GRPR-targeting analogues of bombesin (BN) have successfully
been introduced as potential tracers for visualization and treatment of GRPR-
overexpressing tumours. A previous study showed GRPR-mediated binding of
radiolabelled BN analogues in androgen-dependent but not in androgen-independent
xenografts representing the more advanced stages of PC. We have further investigated
the effect of androgen modulation on GRPR-expression in three androgen-dependent
human PC-bearing xenografts: PC295, PC310 and PC82 using the androgen-
independent PC3-model as a reference. Effects of androgen regulation on GRPR
expression were initially studied on tumours obtained from our biorepository of
xenograft tissues performing RT-PCR and autoradiography (125I-universal-BN). A
prospective biodistribution study (111In-MP2653) and subsequent autoradiography (125I-
GRP and 111In-MP2248) was than performed in castrated and testosterone
resupplemented tumour-bearing mice. For all androgen-dependent xenografts tumour
uptake and binding decreased drastically after 7 days of castration. Resupplementation
of testosterone to castrated animals restored GRPR expression extensively. Similar
findings were concluded from the initial autoradiography and RT-PCR studies. Results
from RT-PCR, for which human specific primers are used, indicate that variations in
GRPR expression can be ascribed to mRNA downregulation and not to castration-
induced reduction in the epithelial fraction of the xenograft tumour tissue. In conclusion
expression of human GRPR in androgen-dependent PC xenografts is reduced by androgen
ablation and is reversed by restoring the hormonal status of the animals. This knowledge
suggests that hormonal therapy may affect GRPR expression in PC tissue making
2GRPR-based imaging and therapy especially suitable for non-hormonally treated PC
patients.
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3Introduction
Prostate cancer (PC) is the third leading cause of cancer-related deaths and the most
frequently diagnosed cancer in men in Western countries 1. PC will increase to be a
major health problem due to the aging of people in the Western world and currently
developed screening strategies that result in diagnosis at more early stage of disease. In
case of metastasised late stage PC standard therapy exists of hormone deprivation which
is initially effective in the majority of patients 2. Eventually however PC patients will
relapse due to progression of PC towards hormone-independent growth of the tumour.
Unfortunately, advanced PC responds poorly to chemotherapeutic agents of which
taxane-based treatments are nowadays considered the standard second-line treatment of
hormone-resistant PC 3, 4. Finally, most patients with metastasised PC will die of
progressive, hormone-independent disease. Treatment and imaging of PC demands for
new concepts, a potential strategy lies in targeting tumour-specific receptors. It could
improve staging of PC determining locality of disease at time of diagnosis which is
required to define treatment decisions.
It has been shown that prostate tumours overexpress the gastrin-releasing
peptide receptor (GRPR) 5-9. Overexpression of these receptors in PC is restricted to the
malignant cells, as normal and hyperplastic prostate tissue were shown to be GRPR-
negative 5. The GRPR is a member of the bombesin (BN) receptor family consisting of
four known receptor subtypes. Three of them the neuromedin B (NMB) receptor (BB1),
GRPR (BB2) and BN receptor subtype 3 (BRS-3 or BB3), are mammalian receptors,
whereas the fourth subtype (BB4) is found only in amphibians 9-13. BN-like receptors,
such as NMB, BB2 and BB3 are involved in the regulation of a large number of
biological processes in the gut and central nervous system 14 and mediate their action by
binding to their BN receptor subtypes. BN analogues are attractive peptides to be used
4to target the GRPR. Its use has been proposed for chemotherapy using cytotoxic BN
analogues and for nuclear interventions employing radiolabelled BN analogues to
perform peptide-receptor scintigraphy and radionuclide therapy (PRRT) 5.
In a previous study we evaluated the expression of GRPRs in different stages of
tumour development using a panel of 12 xenograft models from 9 different patients
representing the various stages of human PC ranging from androgen-dependent to
androgen-independent disease 15, 16. We found GRPR-mediated binding of radiolabelled
BN analogues only in androgen-dependent but not in androgen-independent xenografts
representing the more advanced stages of prostate tumour development 17. Also, in a
pilot study, GRPR-expression of an androgen-dependent xenograft showed reduced
uptake after androgen ablation treatment, suggesting that GRPR-expression may be
influenced by androgens and may be related to the progressive state of PC.
Since the majority of patients are treated with hormonal therapy during the
course of their disease, it is highly relevant to study the impact of hormonal ablation
treatment on GRPR expression in order to reveal whether such patients could still be
eligible to GRPR targeted modalities. Therefore, the purpose of the present study was to
further investigate androgen regulation of the GRPR in three androgen-dependent
human PC xenograft models PC82, PC295 and PC310 that represent the early
androgen-responsive state of human PC 18. We hypothesized that if GRPR is androgen
regulated, the expression is reduced by androgen ablation in androgen-dependent
xenograft-bearing mice, and should be reversed by restoring the hormonal status of the
animals. This experimental design allows to elucidate the direct effects of hormonal
changes on GRPR expression in relevant models for human PC. Since re-
supplementation of patients with testosterone is not likely to be applicable in PC
patients, the present study set-up is merely experimental in nature and less intended to
5mimic the clinical setting. Knowledge about the background of hormonal regulation of
the GRPR will provide crucial information for the clinical use of GRPR-based
technologies. It enables to define patient groups that may benefit from GRPR targeted
modalities. As a reference the androgen-independent xenograft model PC3 was used.
Although PC3 is androgen-independent, GRPR is constitutively overexpressed and,
therefore, this model is frequently used in studies on GRPR expression in PC.
Materials and methods
PC Xenografts
For this study we made use of intact male nude NMRI (Naval Medical Research
Institute) mice (Taconic M&B, Ry, Denmark) 15-17. The experiment was approved by
the Dutch National Animal Experimental Committee and performed in agreement with
The Netherlands Experiments on Animals Act (1977) and the European Convention for
protection of Vertebrate Animals used for Experimental Purposes (Strasbourg, 18
March 1986).
Mice were implanted subcutaneously with small fragments of the androgen-
dependent PC82, PC295 and PC310 human prostate tumour 15. Mice were
supplemented with testosterone to obtain optimal tumour take (80-85%) and tumour
growth by implanting silastic tubings filled with crystalline steroid (6mg/tubing;
AppliChem, Darmstadt, Germany). These implants result in constant delivery of
testosterone exceeding the low physiological levels in intact male nude mice for at least
75 days 19. For the androgen-independent PC3 xenografts, cell suspensions (5 million
cells per mouse) were injected subcutaneously without additional testosterone
supplementation.
6Androgen ablation and testosterone resupplementation
Androgen withdrawal was performed by surgical castration under Ketamin (Alfasan,
Woerden, The Netherlands) and Rompun (Bayer AG, Leverkussen, Germany)
anaesthesia (mix of 1:1), and subsequent removal of testosterone implants. At 2, 4 and 7
days after castration mice were used for biodistribution studies. Control mice were used
when tumour volumes were between 600 and 800mm3, which was reached
approximately 90 days after tumour implantation. Castration of tumour-bearing mice
was planned in such a way that tumour volumes at time of inclusion were in the same
range as those of the control mice.
Resupplementation of testosterone to mice was accomplished under
Ketamin:Rompun anaesthesia by subcutaneous re-implantation of testosterone implants
at 7 days after castration. Biodistribution was then performed at a predefined number of
days after resupplementation (2, 4 or 14 days).
Radiolabelled Peptides
Bombesin analogue [D-Tyr6, -Ala11, Phe13, Nle14]BN(6-14), referred to as universal-
BN, was provided by Biosynthema Inc. (St. Louis, USA) and radiolabelled with 125I as
described previously (radiolabelled compound as from now referred to as 125I-universal-
BN) 20. 125I labelled GRP was obtained commercially from Amersham Biosciences
(Buckinghamshire, United Kingdom).
Bombesin analogues (MP2248) and (MP2653) were provided by Mallinckrodt
Inc. (St. Louis, USA), and radiolabelled with 111In (111InCl3, Tyco Healthcare, Petten,
the Netherlands, DRN 4901, 370 MBq/ml in HCl, pH 1.5-1.9) as described earlier 21-24.
7RNA isolation and quantitative reverse transcriptase polymerase chain reaction (RT-
PCR)
For RT-PCR an independent set of PC82, PC295 and PC310 tumour tissue was
obtained from our biorepository of xenograft tissues (snapfrozen material stored at
minus 80°C) and not from tissues from the biodistribution studies as snapfrozen tissues
are essential to obtain high quality RNA. Tumours from the biodistribution studies
could only be frozen after counting in the gammacounter, which time delay strongly
affects RNA quality.
Total RNA was isolated using RNAzol B kit (Bio-connect, Huissen, The
Netherlands) according to the manufacturer's protocol. The reverse transcriptase
reaction was performed with 1 μg RNA and 100 ng/µl oligo(dT)12-18 primer (Invitrogen,
Carlsbad, CA) for 10 min at 70°C in 11 µl volume and chilled on ice. cDNA was
reverse transcripted in first-strand buffer (4 µl, 5x; Invitrogen) plus 2 µl 100 mM DTT,
1 µl 10 mM dNTP mix, 1µL RNasin ribonuclease inhibitor (Invitrogen) and 200 U
MMLV-RT (Invitrogen) followed by 1 hr incubation at 37°C. The process was
inactivated by heating to 95°C for 10 min samples were than stored at minus 20°C.
Gene expression of GRPR and the housekeeping gene glyceraldehydes-3-
phosphate dehydrogenase (GAPDH) was performed with human-specific primers and
probes purchased as a FAM dye-labelled TaqMan MGB primer probe kit (Applied
Biosystems, Foster City, USA). GAPDH was used as the endogenous reference gene in
order to relate GRPR mRNA levels to the total epithelial (human) cell content of each
sample. The real time PCR reaction was performed in a volume of 25 ul containing
cDNA. PCR mixture contained a final concentration of 360 nM primer, 100 nM probe,
commercially available PCR mastermix (TaqMan Universal PCR Mastermix; Applied
8Biosystems). The PCR mastermix contained 10 mM Tris-HCl (pH 8.3), 50 mM KCl,
5 mM MgCl2, 2.5 mM deoxynucleotide triphosphates, 0.625 U of AmpliTaq Gold DNA
polymerase and 0.25 U AmpErase UNG per reaction. Samples were amplified in an
automated fluorometer (ABI Prism 7700 Sequence Detection System; Applied
Biosystems). Amplification conditions were 2 min at 50°C, 10 min at 95°C, 40 cycles of
15 s at 95°C and 60 s at 60°C. The amount of target gene expressed was related to a
calibrator composed of a mixture of cDNAs from different PC xenografts. Results were
calculated for each cell line as the average relative quantity of the 2 tissue samples
analysed in duplicate.
Statistical analysis was performed using the unpaired 2-tailed t-test using SPSS
15.0 (SPSS Inc., Chicago, United States). A probability of less than 0.05 was considered
significant.
Biodistribution Studies
For biodistribution studies, mice were injected intravenously with 4 MBq / 60 pmol (0.1
µg) / 200 µl of the radiolabelled BN analogue 111In- MP2653 at predefined time points,
and sacrificed 4 hours after peptide injection. Tumour tissue and the GRPR-positive
pancreas as well as kidneys and intestines (relevant organs for clearing) were collected
for counting of radioactivity in a LKB-1282-compugamma system (Perkin Elmer,
Oosterhout, the Netherlands). Radioactive uptake was calculated as % injected dose per
gram of tissue (%ID/g) as a percentage of the control group (100%). Immediately after
counting, the tumours were snapfrozen in liquid nitrogen for autoradiography.
Statistical analysis was performed using the Mann Whitney and unpaired t-test.
A probability of less than 0.05 was considered significant.
9Autoradiographic Analyses
PC xenograft tumour tissues derived from hormonally manipulated mice were evaluated
for GRPR expression by in vitro autoradiography as described previously 17. In short,
frozen xenograft sections (10 µm) were incubated for 1 hour at room temperature with
0.1 nM radiolabeled compound. To discriminate between GRPR-mediated binding and
non-receptor-mediated binding, sections were incubated in the presence of an excess (1
µM) of unlabelled GRP or [Tyr4]BN (Sigma Aldrich, Zwijndrecht, The Netherlands) as
a blocking agent. Sections were exposed to phosphor imaging screens (Perkin Elmer,
Boston U.S.A.) for 16-72 hours. Screens were read using a Cyclone Storage Phosphor
System (Packard, Meriden, USA) and autoradiograms were quantified using Optiquant
Software (Packard, Meriden, USA). Results are indicated as average GRPR-mediated
radiolabelled peptide binding (net Density Light Units/ mm2 of total binding minus non-
specific binding) as a percentage of the control group (100%).
Statistical analysis was performed using the Mann Whitney and unpaired t-test.
A probability of less than 0.05 was considered significant.
Results
Effect of androgens on GRPR mRNA levels: Quantitative RT-PCR
To evaluate changes in mRNA expression of GRPR during androgen manipulation, RT-
PCR was performed on RNA from an independent set of PC82, PC295 and PC310
tumour tissue obtained from our biorepository of xenograft tissues. In order to correct
for variability of stromal (murine) content of the otherwise human (epithelial) tumours,
human-specific probes were used and GRPR mRNA levels were related to GAPDH.
Relative GRPR mRNA levels under control conditions were high for PC295 and PC310
with a mean GRPR/GAPDH ratio of 27.2 and 21.5, respectively. PC82 showed much
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lower GRPR mRNA levels with a mean GRPR/GAPDH ratio of 4.1. After androgen
ablation, the relative GRPR expression dropped considerably for PC295, PC310 and
PC82 (Figure 1). Re-supplementation with testosterone resulted in recovery of GRPR
mRNA levels for all xenografts although recovery levels were quite variable (Figure 1).
Effect of Androgens on GRPR-Mediated Tumour Uptake: Biodistribution Studies
Subsequent to the RT-PCR and initial autoradiography a prospective biodistribution
study was performed to evaluate potential androgen regulation of GRPR and thus the
effect of androgen status on GRPR-mediated tumour uptake in vivo using the
radiolabelled BN analogue 111In-MP2653 in PC tumour-bearing mice under hormonal
manipulation. Table 1 summarizes the results of 3 independent biodistribution studies.
The first experiment was performed with the androgen dependent PC295 xenograft. The
outcome of this study was further substantiated in a subsequent biodistribution study
using the androgen sensitive xenograft PC82 with a more extended time point of
testosterone re-supplementation. Finally, to validate the outcome of these 2
experiments, a third biodistribution study was performed with the androgen sensitive
xenograft models PC295, PC82 and PC310, comparing GRPR expression in intact mice
(control), castrated mice (cas 7), and castrated and re-supplemented mice (cas 7 T 14)
with the androgen-independent PC3 as reference model.
The uptake of the 111In-labeled peptide at 4 hours after injection in the GRPR-
positive tumour and GRPR-expressing pancreas as well as in the clearance organs
(kidneys and intestines) were found to be in agreement with our previous results
obtained with 111In-MP2653 in mice bearing PC3 tumours 25. Tumour and pancreas
uptake in all PC xenografts are summarized in Table 1A. The androgen-dependent PC
tumours demonstrated a significant inhibition of growth after androgen ablation (data
not shown). The androgen-dependent xenografts also show a reduction in tumour uptake
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of 111In-MP2653 after 4 and 7 days of castration. This decline was strongest in PC295
showing a decrease in tumour uptake of 73% (p = 0.0002) after 7 days of castration.
The reduction of peptide uptake in androgen depleted PC82 and PC310 tumours was
less pronounced than in PC295, although still significant (54 % and 41% respectively
after 7 days of castration, p < 0.017).
Re-supplementation of testosterone to castrated mice for 14 days resulted in near
complete recovery of tumour uptake in PC82 and PC310 mice to control levels (86%
and 99%, respectively). For PC295, a partial restoration (40%) of peptide uptake by the
tumours was observed after 4 days of testosterone resupplementation.
Tumour growth of the androgen-independent PC3 model was not affected by
ablation treatment nor by testosterone suppelmentation (data not shown). In contrast to
the androgen sensitive xenografts, tumour uptake of 111In-MP2653 was significantly
increased up to 141% at 7 days post-castration, which was normalized after testosterone
resupplementation.
111In-MP2653 uptake in the GRPR expressing pancreas was similar for all mice
under the various hormonal conditions (Table 1).
Effect of Androgens on GRPR-mediated binding: Autoradiographic Analyses
The effect of androgen status on GRPR-mediated binding in human PC was evaluated
in vitro by autoradiography. Initially, autoradiographic analysis was performed on
tumour sections derived from our biorepository of xenograft tissues (snapfrozen
material stored at minus 80°C) using 125I-universal-BN (74 TBq/mmol). This tumour
collection contained tissues from control mice, castrated mice (castrated 8-10 days prior
to sacrifice) and castrated mice that were resupplemented with testosterone for indicated
days (see Figure 2). Binding of 125I-universal-BN was drastically reduced after androgen
ablation in all 3 androgen-dependent PC xenografts resulting in 95%, 77% and 90%
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reduced binding in PC295, PC310, and PC82, respectively. Testosterone re-
supplementation partially restored binding to 70% and 54% of control level as observed
for PC295 and PC82, respectively, while such restoration of peptide binding was not
observed for PC310 after 13 days of testosterone administration (Figure 2).
Additional autoradiographic evaluations were performed on tumour sections
derived from the prospective biodistribution studies using 125I-GRP (74 TBq/mmol) or
111In- MP2248 (200 MBq/nmol) as ligands. In compliance with the biodistribution
results, PC295 and PC82 showed strong and significant responses to androgen ablation.
After 7 days of castration GRPR-binding was reduced by more than 96% (p <0.0001)
88% (p = 0.0003) for PC295 and PC82, respectively (Figure 3A and B). A partial,
though significant recovery of GRPR-binding was observed for PC295 and PC82 (17%
p = 0.004 and 56% p = 0.0002, respectively) at 4 days of testosterone re-
supplementation with near-complete restoration of receptor-binding at 14 days of
testosterone resupplementation for PC82 (to 91%). For PC310, the reduction in peptide
binding after castration as was less pronounced (45%) and recovery after testosterone
resupplementation was only moderate (Figure 3C). Consistent with the biodistribution
data, the androgen-independent PC3 model demonstrated a rise in GRPR-binding after
testosterone ablation, which was restored to control levels after testosterone
resupplementation (Figure 3D).
Autoradiograms of PC82 tumour sections incubated with 10-10M 111In-MP2248 with or
without blocking agent Tyr4-BN (10-6M) revealed a heterogeneous distribution pattern
of the BN-tracer within these samples (Figure 4).
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Discussion
Opportunistic screening for PC has led to diagnosis of more PC tumours still confined
to the prostate in which curative surgical intervention is still an option. However, due to
lack of accurate imaging modalities for PC, the (micro)metastatic stage of the tumour is
often difficult to determine. The metastatic stage of PC greatly influences prognosis and
determines therapeutic options of the disease. Therefore, reliable and sensitive
diagnostic tools are highly wanted to improve staging at time of diagnosis.
Radiolabelled BN analogues may be promising new radiopharmaceuticals for imaging
and therapy for patients with GRPR-expressing tumours, such as PC 26-31.
Evaluation of GRPR expression throughout the different stages of human
prostate tumour development using a panel of 12 well established human PC xenograft
models has shown that GRPRs were predominantly expressed in androgen-dependent
xenografts and were very low in androgen-independent xenografts 17. This observation
stimulated further research into the potential effects of androgen status on the expression of
the GRPR in PC patients and, consequently, the relevance of their clinical history (therapy
sequence). To further study androgen regulation of the GRPR we used three androgen-
responsive prostate cancer models. We hypothesized that if GRPR-expression was indeed
regulated by androgens, androgen ablation of androgen-dependent xenograft bearing mice
would reduce GRPR expression and recovery of androgen status would induce re-
appearance of GRPR expression. An initial in vitro autoradiographic binding study using
125I-universal-BN as ligand supported our hypothesis. Complete inhibition of GRPR
binding was observed after androgen withdrawal for all xenografts, which could be
recovered after supplementation with testosterone for PC295 and PC82. The reason for the
lack of recovery of GRPR binding in the PC310 tumour is not completely clear. It might
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be related to the shorter resupplementation period indicating that restoration of GRPR
mRNA expression is a relatively slow process. (Figure 2).
RT-PCR study than showed that after ablation of androgens GRPR mRNA
expression was significantly reduced in all androgen-dependent tumour types while
restoration of relative GRPR mRNA levels was achieved after androgen re-
supplementation. Variability in recovery of GRPR may be related to differences in the
kinetics of the process of GRPR translation from mRNA to protein and reappearance.
These results supported our hypothesis that in androgen-dependent xenografts
representing early stage of PC, transcription of GRPR mRNA is androgen regulated.
Subsequent in vivo biodistribution studies were performed with the previously
evaluated 111In-MP2653 analogue 25. Consistent with the autoradiographic results, 111In-
MP2653 tumour uptake was significantly reduced in all three androgen-dependent
xenografts upon castration of tumour-bearing mice, which could be largely restored by
resupplementation with testosterone. GRPR-expression of the androgen independent
PC3 model was not down-regulated by androgen withdrawal. Likewise, uptake of
peptide by the GRPR expressing pancreas was not affected indicating that GRPR
expression in the pancreas was not androgen regulated. These observations were further
substantiated by additional in vitro autoradiographies showing a similar trend in which
castration induced reduction of GRPR binding and testosterone resupplementation induced
restoration of GRPR expression in all 3 models of androgen-regulated human PC.
Although results between biodistribution and autoradiography did show the same trend the
changes in GRPR expression were larger in autoradiography studies. This may be
explained by the more complex physiology of the in vivo biodistribution process that
involves interfering aspects such as in vivo stability of the peptide (affecting retention of
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the peptide/label), tumour vascularisation (influencing uptake), and clearance of the
peptide from the blood 32-34.
We wanted to define to which bombesin receptor(s) variations in binding of 125I-
universal-BN were related and especially if they were exclusively GRPR-related.
Therefore we examined if binding of 125I-universal-BN to the androgen-dependent PC295,
PC310 and PC82 tumour tissues could be blocked by 10-6 M of unlabelled GRP which was
indeed the case (data not shown). Results are consistent with our previous findings 17.
Since 125I-universal-BN binding showed to be exclusively GRPR related the natural
GRPR ligand, 125I-GRP, was employed for a subsequent autoradiography study.
GRP is however a larger peptide than bombesin and therefore it is more
vulnerable to enzymatic degradation, making it is not a very suitable peptide for in vivo
experiments. For this reason the shorter and more stable bombesin analogue 111In-
MP2248 was also used. Similarities between the autoradiographies of both peptides
confirmed that the bombesin analogue In-111-MP2248 indeed targets the GRPR like the
natural GRP peptide. The relatively small variations in absolute values can be explained
by the small differences in GRPR affinities of GRP and MP2248. The present study
showed that peptide uptakes by the tumours are comparable. These data indicate that for
future studies only one peptide, preferably a BN-analogue, may be chosen as the
preferred ligand since this ligand can be employed for both in vitro and in vivo studies.
PC3 is a GRPR expressing androgen-independent model of human PC that is
extensively used in literature. It has no androgen receptor and lacks the ability to
produce PSA. Although GRPR is constitutively active in PC3 and the model is not
suitable for studying androgen regulation of GRPR, its use in the field of bombesin-
targeted imaging of PC obliged its use as reference model in this study. Our results
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confirm that GRPR expression in PC3 xenografts is not downregulated by castration
and upregulated by resupplementation of androgens.
Xenograft tumour tissue consists of human epithelial tumour cells and
supportive stromal cells originating from the mouse. Androgen-dependent PC
xenografts will have regression of epithelial tumour fraction upon androgen ablation.
Consequently tumours in such xenografts will contain less (human) epithelial cells as
compared to the (non androgen responsive) stromal compartment. It was essential to
verify whether the observed effects were caused by regulation of GRPR expression
itself or by changes in the total epithelial (human) content of the xenograft. RT-PCR
enables to correct for these changes while expression of GRPR mRNA was related to
GAPDH mRNA expression levels using human-specific primer probe sets for both
GRPR and GAPDH hereby excluding the non human stromal compartment.
Although none of our xenograft models representing late stage disease expressed
GRPR 35, it cannot be excluded that GRPR may be re-expressed in progressive, late
stage disease as has been suggested from patient samples 5 and few patients in clinical
studies 31.
Conclusion
GRPR-binding of androgen-dependent human PC xenograft models is androgen-
regulated. Androgen ablation results in down-regulation of GRPR expression. This
expression can be (partially) restored by subsequent resupplementation with
testosterone. Data further showed that the decline in GRPR-binding is the result of
GRPR mRNA down-regulation rather than the consequence of the castration-induced
reduction in the epithelial fraction of the xenograft. This suggests that hormonal therapy
may affect GRPR expression in early stage, hormonally-treated patients with PC. Our
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observations do not exclude, however, that GRPR expression may reappear in
progressive late stage patients.
Our data indicate that GRPR is a promising target for imaging of early PC in
patients that have not been treated by hormonal therapy. GRPR-based imaging modalities
may thus be used to improve staging of hormone naïve patients with PC. Its potential as a
therapeutic modality for PC may be limited to non-hormonally treated patients, although
reports suggest that GRPR may be reexpressed at later stages of PC. Studies are
underway to further validate and compare GRPR expression in tumour tissue derived
from both hormonally treated and untreated patients at different stages of PC.
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Legends
Table 1
Results of biodistribution and in vitro autoradiographic studies.
A Biodistribution results are average tumour and pancreas uptake of 111In-MP2653 (%
injected dose / gram tissue) as percentage of controls (100%) per hormonally
manipulated group, data are expressed as mean ± SD. Numbers of animals used per
group are stated under (n).
B + C In vitro autoradiography results are average GRPR-mediated binding (net
Density Light Units / mm2 of total binding minus non-specific binding) as percentage of
controls (100%) of 125I-GRP (B) and 111In-MP2248 (C) data are expressed as mean ±
SD. Numbers of animals used per group are stated under (n).
cas = castration (for 2, 4 or 7 days); T = testosterone resupplementation for 2, 4, or 14
days; nd= not determined. * = significantly different from control group (p < 0.05); **
= significantly different from castration for 7 days group (p < 0.05). # Groups consist
of pancreas from non tumour-bearing and tumour bearing androgen supplemented,
castrated and castrated subsequently resupplemented intact mice.
Figure 1
Results of RT-PCR performed in androgen-dependent PC bearing mice; PC295 (A),
PC82 (B) and PC310 (C). Tumour tissue was obtained from control mice, castrated
mice (castration 9-22 days before tumour collection) or castrated mice that were
testosterone resupplemented (castration 12-22 days before testosterone
resupplementation of 7-45 days). Each tissue sample was performed in duplicate.
Results are shown as an average of the two GRPR/GAPDH measurements (mean ± SD).
* = statistically significant difference compared to the mean of the control group (p <
0.05).
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Figure 2
GRPR-specific binding of 125I-universal-BN (= total binding 125I-universal-BN 10-10M)
minus non-specific binding (125I-universal-BN 10-10M + GRP 10-6M) to androgen-
dependent PC xenograft sections. Tumour tissue was obtained from control mice,
castrated mice (castration 7-10 days before tumour collection) or castrated mice that
were testosterone resupplemented (castration + testosterone= 57 + 38 days, 29 + 13
days and 20 + 22 days respectively for PC295, PC310 and PC82). Results are shown as
average net Density Light Units per mm2 (net DLU/mm2). Results are average from 3
independent samples (except for the castration + testosterone group of which we had 1
sample) ± SD. We used 2-4 sections per independent sample.
Figure 3
Receptor-mediated binding of 111In-MP2248 to androgen-dependent PC295 (A), PC82
(B), PC310 (C), and androgen-independent PC3 (D) xenograft sections. Tumour tissue
was derived from the tumour-bearing mice from the biodistribution study.
Autoradiography results are average receptor-mediated binding (net Density Light
Units/ mm2 of total binding minus non-specific binding) as percentage of the control
group (100%) ± SEM. N = 4-14 xenografts / group, 2 sections per xenograft tumour
were used.
cas = castration for 2, 4 or 7 days; T = testosterone resupplementation for 2, 4, or 14
days; * = significantly different from control group (p < 0.05); ** = significantly
different from cas 7 group (p < 0.05).
Figure 4
In vitro autoradiograms of PC82 tumour sections incubated with 10-10M 111In-MP2248
with or without an additional blocking agent Tyr4-BN (10-6M). Xenografts were
23
derived from castrated and testosterone resupplemented mice used in the
biodistribution.
Table 1
Group study PC295 PC82 PC310 PC3 Pancreas#
% control (n) % control (n) % control (n) % control (n) % control (n)
control A uptake 111In-MP2653 100 ± 31 (11) 100 ± 31 (14) 100 ± 19 (4) 100 ± 33 (12) 100 ± 21 42
B binding 125I-GRP 100 ± 19 100 ± 37 100 ± 67 100 ± 53
C binding 111In-MP2248 100 ± 36 100 ± 54 100 ± 25 100 ± 42
cas 2 A uptake 111In-MP2653 124 ± 29 (5) 109 ± 37 (3)
B binding 125I-GRP 72 ± 6.9* 67 ± 26
C binding 111In-MP2248 55 ± 17* 67 ± 28
nd nd nd
cas 4 A uptake 111In-MP2653 22 ± 7.3* (5) 56 ± 30 (3)
B binding 125I-GRP 11 ± 8.1* 29 ± 27*
C binding 111In-MP2248 6.5 ± 6.4* 27 ± 30
nd nd nd
cas 7 A uptake 111In-MP2653 27 ± 22* (12) 46 ± 17* (8) 59 ± 4.0* (5) 141 ± 24* (5) 101 ± 32 33
B binding 125I-GRP 3.4 ± 1.9* 12 ± 5.3* 55 ± 14 123 ± 54
C binding 111In-MP2248 1.5 ± 0.8* 7.7 ± 3.8* 52 ± 28 120 ± 19
cas 7 T 2 A uptake 111In-MP2653 35,8 ± 11 (5) 62 ± 10 (3)
B binding 125I-GRP 20 ± 6.0** 33 ± 4.6**
C binding 111In-MP2248 14 ± 6.5** 28 ± 6.4**
nd nd nd
cas 7 T 4 A uptake 111In-MP2653 40 ± 9.4 (4) 107 ± 12** (3)
B binding 125I-GRP 30 ± 9.7** 60 ± 23**
C binding 111In-MP2248 17 ± 6.3** 56 ± 10**
nd nd nd
cas 7 T 14 A uptake 111In-MP2653 86 ± 46 (8) 99 ± 30** (5) 95 ± 47 (5) 99 ± 17 20
B binding 125I-GRP 91 ± 30** 50 ± 19 112 ± 76
C binding 111In-MP2248
nd
87 ± 40** 83 ± 21 125 ± 49
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